Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GOSS NASDAQ:KALV NASDAQ:NKTX NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOSSGossamer Bio$2.56+5.8%$2.51$0.66▼$3.60$550.26M1.944.19 million shs3.04 million shsKALVKalVista Pharmaceuticals$11.81+2.8%$13.16$7.30▼$17.28$580.51M-0.151.57 million shs864,202 shsNKTXNkarta$2.36+12.9%$2.12$1.31▼$4.55$148.44M0.86858,932 shs3.28 million shsSVRASavara$3.42-1.4%$3.29$1.89▼$4.30$599.74M0.461.15 million shs1.21 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOSSGossamer Bio-3.20%-2.81%-9.02%+77.94%+137.25%KALVKalVista Pharmaceuticals+5.22%-4.65%-28.01%-25.92%+2.50%NKTXNkarta+1.46%-1.88%-1.42%+16.11%-46.41%SVRASavara+1.17%-1.98%-9.87%+50.87%-8.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOSSGossamer Bio$2.56+5.8%$2.51$0.66▼$3.60$550.26M1.944.19 million shs3.04 million shsKALVKalVista Pharmaceuticals$11.81+2.8%$13.16$7.30▼$17.28$580.51M-0.151.57 million shs864,202 shsNKTXNkarta$2.36+12.9%$2.12$1.31▼$4.55$148.44M0.86858,932 shs3.28 million shsSVRASavara$3.42-1.4%$3.29$1.89▼$4.30$599.74M0.461.15 million shs1.21 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOSSGossamer Bio-3.20%-2.81%-9.02%+77.94%+137.25%KALVKalVista Pharmaceuticals+5.22%-4.65%-28.01%-25.92%+2.50%NKTXNkarta+1.46%-1.88%-1.42%+16.11%-46.41%SVRASavara+1.17%-1.98%-9.87%+50.87%-8.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGOSSGossamer Bio 2.67Moderate Buy$8.50232.03% UpsideKALVKalVista Pharmaceuticals 2.90Moderate Buy$26.43123.78% UpsideNKTXNkarta 2.50Moderate Buy$13.50472.03% UpsideSVRASavara 2.57Moderate Buy$7.50119.30% UpsideCurrent Analyst Ratings BreakdownLatest NKTX, SVRA, KALV, and GOSS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025GOSSGossamer BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025KALVKalVista PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NKTXNkartaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SVRASavaraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GOSSGossamer BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025KALVKalVista PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NKTXNkartaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SVRASavaraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/12/2025KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$28.009/12/2025KALVKalVista PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$27.00 ➝ $28.009/11/2025GOSSGossamer BioCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGOSSGossamer Bio$114.70M5.07N/AN/A$0.13 per share19.69KALVKalVista PharmaceuticalsN/AN/AN/AN/A$1.92 per shareN/ANKTXNkartaN/AN/AN/AN/A$5.78 per shareN/ASVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGOSSGossamer Bio-$56.53M-$0.62N/AN/AN/A-344.81%-1,774.72%-46.73%11/6/2025 (Estimated)KALVKalVista Pharmaceuticals-$183.44M-$3.94N/AN/AN/AN/A-195.62%-89.96%12/4/2025 (Estimated)NKTXNkarta-$108.79M-$1.48N/AN/AN/AN/A-27.74%-22.38%11/6/2025 (Estimated)SVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest NKTX, SVRA, KALV, and GOSS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025GOSSGossamer Bio-$0.19N/AN/AN/A$6.32 millionN/A11/6/2025Q3 2025NKTXNkarta-$0.32N/AN/AN/AN/AN/A9/11/2025Q1 2026KALVKalVista Pharmaceuticals-$0.91-$1.12-$0.21-$1.12$1.97 million$1.43 million8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/12/2025Q2 2025NKTXNkarta-$0.37-$0.31+$0.06-$0.31N/AN/A8/5/2025Q2 2025GOSSGossamer Bio-$0.18-$0.17+$0.01-$0.17$4.12 million$11.49 million7/10/2025Q4 2025KALVKalVista Pharmaceuticals-$0.83-$3.69-$2.86-$0.99$4.20 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGOSSGossamer BioN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGOSSGossamer BioN/A4.404.40KALVKalVista PharmaceuticalsN/A5.375.37NKTXNkartaN/A15.6715.67SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGOSSGossamer Bio81.23%KALVKalVista PharmaceuticalsN/ANKTXNkarta80.54%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipGOSSGossamer Bio6.70%KALVKalVista Pharmaceuticals4.30%NKTXNkarta8.40%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGOSSGossamer Bio180227.38 million212.15 millionOptionableKALVKalVista Pharmaceuticals10050.52 million48.35 millionOptionableNKTXNkarta14071.03 million65.06 millionOptionableSVRASavara20172.84 million163.63 millionOptionableNKTX, SVRA, KALV, and GOSS HeadlinesRecent News About These CompaniesSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara5 hours ago | prnewswire.comShareholders that lost money on Savara Inc.(SVRA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn MoreOctober 9 at 4:22 PM | globenewswire.comShareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRAOctober 9 at 8:45 AM | prnewswire.comSavara: Back On Track With Upcoming APAP BLA FilingOctober 9 at 7:42 AM | seekingalpha.comSavara Inc. INVESTOR ALERT: Kirby McInerney LLP Reminds Savara Inc. Investors of Looming Lead ...October 9 at 4:38 AM | caledonianrecord.comCWeiss Ratings Reaffirms Sell (D-) Rating for Savara (NASDAQ:SVRA)October 9 at 2:26 AM | marketbeat.comSavara Inc. INVESTOR ALERT: Kirby McInerney LLP Reminds Savara Inc. Investors of Looming Lead Plaintiff Deadline in Class Action LawsuitOctober 8 at 6:00 PM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRAOctober 8 at 4:30 PM | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– SVRAOctober 8 at 11:28 AM | globenewswire.comSVRA DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraOctober 8 at 11:10 AM | globenewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 DeadlineOctober 8 at 4:10 AM | theglobeandmail.comSavara Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights - SVRAOctober 7 at 5:58 PM | theglobeandmail.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud LawsuitOctober 7 at 4:17 PM | prnewswire.comSavara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitOctober 7 at 3:57 PM | prnewswire.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 7 at 7:42 AM | prnewswire.comSavara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRAOctober 7 at 7:40 AM | prnewswire.comSavara Inc. INVESTOR ALERT: Kirby McInerney LLP Reminds Savara Inc. Investors of Looming Lead Plaintiff Deadline in Class Action LawsuitOctober 6 at 6:00 PM | globenewswire.comLost Money on Savara Inc. (SVRA)? Join Class Action Suit Seeking Recovery – Contact Levi & KorsinskyOctober 6 at 4:48 PM | globenewswire.comDeadline Alert: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitOctober 6 at 4:45 PM | globenewswire.comSAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of the November 7th Deadline in The Savara Class Action LawsuitOctober 6 at 2:25 PM | globenewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRAOctober 6 at 8:45 AM | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNKTX, SVRA, KALV, and GOSS Company DescriptionsGossamer Bio NASDAQ:GOSS$2.56 +0.14 (+5.79%) Closing price 04:00 PM EasternExtended Trading$2.58 +0.02 (+0.59%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.KalVista Pharmaceuticals NASDAQ:KALV$11.81 +0.32 (+2.79%) Closing price 04:00 PM EasternExtended Trading$11.52 -0.29 (-2.49%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.Nkarta NASDAQ:NKTX$2.36 +0.27 (+12.92%) Closing price 04:00 PM EasternExtended Trading$2.35 -0.01 (-0.64%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Savara NASDAQ:SVRA$3.42 -0.05 (-1.44%) Closing price 04:00 PM EasternExtended Trading$3.42 +0.00 (+0.15%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
